PASCAL BIOSCIENCES INC.
Condensed Consolidated Interim Financial Statements
For the Six Months Ended May 31, 2021 and 2020

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

In accordance with National Instrument 51-102, released by the Canadian Securities Administrators, the Company discloses that its independent auditors have not reviewed the condensed consolidated interim financial statements for the six months ended May 31, 2021 and 2020.

Pascal Biosciences Inc.
Condensed Consolidated Interim Statements of Financial Position
Unaudited – Prepared by Management
(Expressed in Canadian Dollars)

For the periods Ended:	*Notes*	**May 31, 2021**	**November 30, 2020**
ASSETS		**$**	**$**
Current			
Cash and cash equivalents		155,048	-
Prepaid expenses		13,383	10,598
Receivables	6,11	67,578	83,802
Total current assets		236,009	94,400
Equipment	4	17,576	26,314
Total assets		253,585	120,714
LIABILITIES			
Current liabilities			
Bank indebtedness		-	16,909
Accounts payable and accrued liabilities	8	306,741	326,494
Short-term loan payable	8	144,864	129,650
Total liabilities		451,605	473,053
SHAREHOLDERS' EQUITY (DEFICIENCY)			
Equity attributable to shareholders			
Share capital	5	13,008,587	12,331,652
Subscriptions receivable	5	(158,635)	-
Reserves	5	969,400	887,921
Deficit		(14,017,372)	(13,571,912)
Total shareholders' equity (deficiency)		(198,020)	(352,339)
Total liabilities and shareholders' equity (deficiency)		253,585	120,714

Approved on behalf of the Board:

"Patrick W. Gray" — Director

"Terry Pearson" — Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Pascal Biosciences Inc.

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

		For the Three Months Ended May 31,		For the Six Months Ended May 31,	
	Notes	**2021**	**2020**	**2021**	**2020**
		$	**$**	**$**	**$**
General and administrative expenses					
Accounting and audit fees		-	6,354	-	6,354
Administrative and general office		15,070	14,019	31,293	32,833
Amortization	4	7,068	6,934	8,738	2,198
Bank charges and interest		1,673	1,521	3,501	3,697
Consulting fees	8	24,447	35,177	57,586	136,592
Salaries and benefits	8	277,366	308,614	512,743	617,721
Foreign exchange loss		(20,844)	4,216	(15,717)	14,305
Insurance		7,819	15,035	19,950	31,747
Investor relations and marketing		35,565	-	38,272	9,000
Legal fees		1,552	19	1,552	652
Research and development	6,11	(143,258)	14,786	(299,518)	29,767
Share-based payments	5, 8	70,826	3,962	71,979	12,230
Transfer agent, listing and filing fees		8,805	10,226	15,057	18,217
Travel and entertainment		-	5	24	165
Total general and administrative expenses		(286,089)	(420,868)	(445,460)	(915,478)
Other Income					
Interest income		-	(297)	-	416
Net loss and comprehensive loss for the year		(286,089)	(421,165)	(445,460)	(915,062)
Loss per share, basic and diluted		(0.00)	(0.01)	(0.01)	(0.02)
Weighted average common shares outstanding - basic and diluted		64,764,334	54,069,977	61,865,099	52,988,815

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Pascal Biosciences Inc.
Condensed Consolidated Interim Statements of Shareholders' Equity (Deficiency)

Unaudited – Prepared by Management
(Expressed in Canadian Dollars)

	Common Shares					Total
	Number of Shares	Amount	Share Subscriptions Receivable	Option Reserve	Deficit	Shareholders' Equity (Deficiency)
		$	$	$	$	$
Balance, November 30, 2019	52,647,396	11,805,621	-	1,115,120	(12,576,705)	344,036
Shares issued for cash	3,793,548	341,419	-	-	-	341,419
Share-based payments	-	-	-	12,230	-	12,230
Net loss for the period	-	-	-	-	(915,062)	(915,062)
Balance, May 31, 2020	56,440,944	12,147,040	-	1,127,350	(13,491,767)	(217,377)
Shares issued for debt	1,153,825	184,612	-	-	-	184,612
Share-based payments	-	-	-	3,291	-	3,291
Fair value transfer on expiry of options	-	-	-	(242,720)	242,720	-
Net loss for the period	-	-	-	-	(322,865)	(322,865)
Balance, November 30, 2020	57,594,769	12,331,652	-	887,921	(13,571,912)	(352,339)
Shares issued for cash	7,500,000	740,500	-	9,500	-	750,000
Share issuance costs	-	(63,565)	-	-	-	(63,565)
Subscriptions receivable	-	-	(158,635)	-	-	(158,635)
Share-based payments	-	-	-	71,979	-	71,979
Net loss for the period	-	-	-	-	(445,460)	(445,460)
Balance, May 31, 2021	**65,094,769**	**13,008,587**	**(158,635)**	**969,400**	**(14,017,372)**	**(198,020)**

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Pascal Biosciences Inc.

Condensed Consolidated Interim Statements of Cash Flows

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

	May 31, 2021	May 31, 2020
	$	$
Cash provided by (used in):		
Operating activities:		
Net loss for the period:	(445,460)	(915,062)
Items not involving cash:		
Amortization	8,738	2,198
Share-based payments	71,979	12,230
Changes in non-cash working capital:		
Prepaid expenses	(2,785)	(2,963)
Accounts receivable	16,224	(517)
Accounts payable and accrued liabilities	(36,662)	371,260
Due to related parties	15,214	-
	(372,752)	(532,854)
Financing activities:		
Shares issued for cash	750,000	341,419
Share issuance costs	(63,565)	-
Share subscriptions receivable	(158,635)	-
	527,800	341,419
Net change in cash and cash equivalents	155,048	(191,435)
Cash and cash equivalents, beginning of period	-	374,851
Cash and cash equivalents, end of period	155,048	183,416
Composition of cash and cash equivalents		
Cash	155,048	147,607
Cash in asset held for sale	-	35,809
Cash and cash equivalents, end of period	155,048	183,416

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

1. NATURE OF OPERATIONS AND GOING CONCERN

Pascal Biosciences Inc. (the "Company") was incorporated on January 28, 2011 pursuant to the *Business Corporations Act* (British Columbia). On May 24, 2013, the Company acquired all of the issued and outstanding shares of bioMmune Advanced Technologies Inc. ("BAT"), a private company (incorporated on July 5, 2012) formed to commercially exploit a number of patents and patent applications that surround three technologies. On March 27, 2017, the Company incorporated a wholly owned subsidiary in Seattle, Washington, named Pascal Biosciences US, Inc. ("Pascal (US)"). The Company is a Tier 2 Biotechnology Issuer engaged in the research and development of products for the treatment of cancers and for improvement of the immune system, trading on the TSX Venture Exchange (the "Exchange") under the trading symbol "PAS".

The Company's head office and registered records office is Suite 304, 4000 Mason Road, Seattle WA 98195.

The Company has not generated any revenues and has incurred losses since inception. The Company expects to spend a significant amount of capital to fund research and development. As a result, the Company expects that its operating expenses will increase significantly, and consequently, will require significant revenues to become profitable. Even if the Company does become profitable, it may not be able to sustain or increase profitability on a quarterly or annual basis. The Company cannot predict when, if ever, it will be profitable. There can be no assurances that the intellectual property of the Company, or other technologies it may acquire, will meet applicable regulatory standards, obtain required regulatory approvals, be capable of being produced in commercial quantities at reasonable costs, or be successfully marketed. The Company plans to undertake additional laboratory and animal studies with respect to its intellectual property, and there can be no assurance that the results from such studies or trials will result in a commercially viable product or will not identify unwanted side effects.

These condensed consolidated interim financial statements have been prepared under the assumption of a going concern, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at May 31, 2021, the Company has an accumulated deficit of $14,017,372 (November 30, 2020: $13,571,912) and reported a net loss of $445,460 (2020: $915,062). The Company's ability to maintain its existence is dependent upon the continuing support of its creditors and its success in obtaining new equity financing for its ongoing operations. Financing options available to the Company include equity financings and loans. These conditions indicate the existence of material uncertainties that may cast significant doubt as to the ability of the Company to meet its obligations as they come due, and accordingly, the appropriateness of the use of accounting principles applicable to a going concern. Realization values of the Company's assets may be substantially different from carrying values as shown in these condensed consolidated interim financial statements and, accordingly, should the Company be unable to continue as a going concern, the adjustments could be material.

Since January 2020, the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19", has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and physical distancing, have caused material disruption to business globally resulting in an economic slowdown. Global equity markets have experienced significant volatility. The duration and enduring impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results, condition, and financings (equity and debt) of the Company in future periods.

2. STATEMENT OF COMPLIANCE, BASIS OF PRESENTATION

(a) Statement of compliance

These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") and International Accounting Standards, as issued by the International Accounting Standards Board ("IASB").

These condensed consolidated interim financial statements were authorized for issue by the Board of Directors on July 28, 2021.

(b) Basis of measurement

These condensed consolidated interim financial statements have been prepared on a historical cost basis, except for financial instruments classified as fair value through profit or loss ("FVTPL"), which are stated at their fair values. In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

The preparation of financial statements in compliance with IFRS requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The areas involving a higher degree of judgment of complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 3.

(c) Functional and presentation currency

These condensed consolidated interim financial statements are presented in Canadian dollars, which is the functional currency of the Company and its wholly owned subsidiaries, BAT and Pascal (US).

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

These condensed consolidated interim financial statements are unaudited and have been prepared in accordance with International Financial Reporting Standards ("IFRS") and in accordance with the International Accounting Standards ("IAS") 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). The accounting policies and methods of computation applied by the Company in these condensed consolidated interim financial statements are the same as those applied in the Company's annual consolidated financial statements as at and for the year ended November 30, 2020.

(Expressed in Canadian Dollars)

4. EQUIPMENT

Cost		**Lab Equipment**		**Computer Equipment**		**Total**
Balance November 30, 2019	$	9,870	$	4,401	$	14,271
Transfer from assets held for sale		57,358		-		57,358
Balance November 30, 2020 and May 31, 2021	$	67,228	$	4,401	$	71,629
Accumulated Amortization						
Balance, November 30, 2019	$	7,176	$	149	$	7,325
Transfer to assets held for sale		25,512		-		25,512
Charge for the year		12,278		200		12,478
Balance November 30, 2020	$	44,966	$	349	$	45,315
Charge for the period		7,624		1,114		8,738
Balance May 31, 2021	$	52,590	$	1,463	$	54,053
Carrying Value						
Balance, November 30, 2020	$	22,262	$	4,052	$	26,314
Balance, May 31, 2021	$	14,638	$	2,938	$	17,576

5. SHARE CAPITAL

(a) Authorized

The authorized share capital of the Company consists of an unlimited number of common shares without par value.

(b) Common shares

Six months ended May 31, 2021

On February 8, 2021, the Company closed the first tranche of a private placement announced November 2, 2020 and January 19 and January 22, 2021, for 5,600,000 Units at a price of $0.10 per Unit and gross proceeds of $560,000. Each Unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one additional common share of the Company at a price of $0.15 for a period of 24 months from the date of closing, subject to an acceleration clause which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $0.40 for 10 consecutive trading days. The warrants will expire upon 30 days from the date the Company provides notice in writing to the warrant holders via a news release.

On March 17, 2021, the Company closed the second tranche of the non-brokered private placement announced on November 2, 2020 and January 19 and January 22, 2021, and issued 1,900,000 Units at a price of $0.10 per Unit for gross proceeds of $190,000. Each Unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder

(Expressed in Canadian Dollars)

5. SHARE CAPITAL (continued)

(b) Common shares (continued)

to purchase one additional common share of the Company at a price of $0.15 for a period of 24 months from the date of closing, subject to an acceleration clause, under which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $0.40 for 10 consecutive trading days. The warrants will expire upon 30 days from the date the Company provides notice in writing to the warrant holders via a news release, The Company paid $1,365 in finder's fees related to the closing of the second tranche. The Company allocated $9,500 of the gross proceeds to warrants using the residual method. At May 31, 2021, the Company had subscriptions receivable of $158,635.

Six months ended May 31, 2020

On March 24, 2020, the Company completed a non-brokered private placement for gross proceeds of $341,419 and issued 3,793,548 units (each a "Unit") to SoRSE Technology Corporation (the "Purchaser"), at a price of $0.09 per Unit. Each Unit consists of one common share and one common share purchase warrant (each a "Warrant"). Each Warrant will entitle the Purchaser to purchase one additional common share at a price of $0.15 until March 24, 2022.

(c) Stock options

During the year ended November 30, 2012, the Company adopted a stock option plan, which provides that the Board of Directors may from time to time, in its discretion, and in accordance with the Exchange requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares and exercisable for five years from the date of grant.

A summary of the Company's outstanding stock options and changes is as follows:

	Quantity	**Weighted Average Exercise Price ($)**
Outstanding, November 30, 2019	5,050,000	0.33
Expired	(1,135,000)	0.34
Outstanding, November 30, 2020	3,915,000	0.38
Granted	3,275,000	0.09
Expired	(685,000)	0.36
Outstanding, May 31, 2021	6,505,000	0.23
Exercisable as at May 31, 2021	3,264,000	0.37

On April 20, 2021 the Company granted an aggregate of 2,875,000 stock options to directors, employees and consultants, pursuant to the Company's stock option plan and subject to the

5. SHARE CAPITAL (continued)

(c) Stock options (continued)

policies of the TSX Venture Exchange. The stock options are exercisable at a price of $0.08 per share, exercisable for a period of five years and will vest quarterly over one year. The fair value of the stock options was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions: risk-free interest rate of 0.75%, expected dividend rate of 0%; expected volatility of 94.59% and forfeiture rate of 0%. The fair value of the options was calculated at $164,478. The share-based payment expense recognized during the six months ended May 31, 2021 was $38,488 (2020: $nil).

On December 18, 2020, the Company granted 400,000 stock options to directors and employees of the Company. The stock options are exercisable at a price of $0.15, for a period of five years and vest quarterly over one year. The fair value of the stock options was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions: risk-free interest rate of 0.35%, expected dividend rate of 0%; expected volatility of 94.21% and forfeiture rate of 0%. The fair value of the options was calculated at $42,621. The share-based payment expense recognized during the six months ended May 31, 2021 was $31,422 (2020: $nil).

On May 28, 2019, the Company granted 198,000 stock options to consultants, exercisable at a price of $0.20 per share. The stock options will vest quarterly over 36 months and expire on May 28, 2022. The fair value of the stock options was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions: risk-free interest rate of 1.48%, expected dividend rate of 0%; expected volatility of 87.39% and forfeiture rate of 0%. The fair value of the options was calculated at $21,651. The share-based payment expense recognized during the six months ended May 31, 2021 was $2,069 (2020: $5,138).

On August 3, 2018, the Company granted 2,100,000 stock options to officers, directors and consultants, exercisable at a price of $0.35 per share. 1,475,000 of the stock options will vest quarterly over 12 months and expire on August 3, 2023. 625,000 of the stock options will vest quarterly over 24 months and expire on August 3, 2021. The fair value of 1,475,000 of the stock options granted was estimated using the Black-Scholes option-pricing model with the following assumptions: risk-free interest rate of 2.35%, expected dividend rate of 0%; expected volatility of 93.22% and forfeiture rate of 0%. The fair value of the stock options was estimated at $372,000. The fair value of 625,000 of the stock options granted was estimated using the Black-Scholes option-pricing model with the following assumptions: risk-free interest rate of 2.35%, expected dividend rate of 0%; expected volatility of 97.21%; and forfeiture rate of 0%. The fair value of the stock options was estimated at $134,324. The share-based payment expense recognized during the year ended November 30, 2020 was $7,091.

Option pricing models require the use of highly subjective estimates and assumptions. The expected volatility assumption is based on the historical and implied volatility of the Company's common share price on the Exchange. The risk-free interest rate assumption is based on yield curves on Canadian government zero-coupon bonds with a remaining term equal to the stock options' expected life. The Company uses historical data to estimate option exercise, forfeiture and employee termination within the valuation model. Based on the best estimate, management

(Expressed in Canadian Dollars)

5. SHARE CAPITAL (continued)

(c) Stock options (continued)

applied the estimated forfeiture rate of 0% in determining the expense recorded in the accompanying condensed consolidated interim statements of operations and comprehensive loss.

The options outstanding at May 31, 2021 are as follows:

Expiry Date	Outstanding	Exercisable	Weighted Average Exercise Price ($)	Weighted Average Remaining Contractual Life (Years)
August 2, 2021	325,000	325,000	0.35	0.17
October 3, 2021	392,000	392,000	0.72	0.34
May 28, 2022	198,000	132,000	0.20	0.99
June 27, 2022	590,000	590,000	0.33	1.07
January 28, 2023	250,000	250,000	0.29	1.66
August 2, 2023	1,475,000	1,475,000	0.35	2.17
December 18, 2025	400,000	100,000	0.15	4.55
April 20, 2026	2,875,000	-	0.08	4.89
	6,505,000	3,264,000	0.23	3.15

(d) Share purchase warrants

A summary of the Company's outstanding share purchase warrants and changes is as follows:

	Quantity	Weighted Average Exercise Price ($)	Weighted Average Remaining Contractual Life (Years)
Balance, November 30, 2019	387,594	0.40	0.27
Issued	3,793,548	0.15	1.31
Expired	(387,594)	0.40	-
Balance, November 30, 2020	3,793,548	0.15	1.31
Issued	7,500,000	0.15	1.72
Balance, May 31, 2021	11,293,548	0.15	1.41

(Expressed in Canadian Dollars)

5. SHARE CAPITAL (continued)

(d) Share purchase warrants (continued)

The warrants outstanding at May 31, 2021 are as follows:

Expiry Date	Number Outstanding	Weighted Average Exercise Price ($)	Weighted Average Remaining Contractual Life (Years)
March 24, 2022	3,793,548	0.15	0.81
February 8, 2023	5,600,000	0.15	1.69
March 17, 2023	1,900,000	0.15	1.79
	11,293,548	0.15	1.41

6. COLLABORATIVE RESEARCH AGREEMENT

On September 14, 2020, the Company and SōRSE announced that they have entered into a Collaborative Research Agreement (the "Agreement") to advance Pascal's immune-stimulating cannabinoid PAS-393 into clinical testing in humans. Pascal (US) and SōRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors.

SōRSE will provide US $750,000 in research funding to Pascal (US) throughout the 15-month collaboration and will pay for related research expenditures. During the six months ended May 31, 2021, the Company received $377,142 (US $300,000) of research funding which is included in research and development.

7. CAPITAL RISK MANAGEMENT

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of any identified business opportunities and to maintain a flexible capital structure for the benefit of its stakeholders.

The Company includes shareholders' equity (deficiency), comprised of issued share capital, reserves and deficit in the definition of capital.

The Company manages the capital structure and makes adjustments to it in light of changes in the economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, enter into joint venture arrangements, acquire or dispose of assets, or adjust the amount of cash.

The Board of Directors does not establish quantitative return on capital criteria for management but rather relies on the expertise of the Company's management to manage its capital to be able to sustain the future development of the Company's business. The Company is not subject to externally imposed capital requirements. There were no changes in the Company's approach to capital management during the six months ended May 31, 2021.

8. RELATED PARTY TRANSACTIONS

The following is a summary of related party transactions that occurred during the three and six months ended May 31, 2021 and 2020.

			Three months ended May 31,		Six months ended May 31,
Services provided by:		**2021**	**2020**	**2021**	**2020**
		$	**$**	**$**	**$**
Key management salaries/fees	a)	60,157	66,787	131,174	168,297
Director and officer salaries/fees	b)	129,472	100,855	228,092	340,896
Benefits		30,999	35,405	60,792	69,888
Share-based payments		34,334	-	43,155	-
		254,962	203,047	463,213	579,081

Related parties include:

a) Key management salaries include amounts paid to the CEO and the CFO.

b) Director and officer salaries include amounts paid to the Vice President of Research, the Vice President of Therapeutic Development and the Chief Business Officer.

Included in accounts payable and accrued liabilities is $151,724 (November 30, 2020: $69,522) payable to directors and officers of the Company. Included in the above are loans to the Company by a director of the Company totaling $144,864 (US $120,000). The loan is unsecured, is due on demand and bears no interest.

9. COMMITMENTS

Commitments over the next five fiscal years are as follows:

a) Consulting agreement for bookkeeping services to Pascal (US) for an annual fee of US $24,000.

The Company has also entered into the following agreements:

a) University of Washington: On October 9, 2018, the Company entered into an exclusive license agreement with the University of Washington ("UW") to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases. Under the terms of the agreement, the Company will pay the annual fees (US Dollars) as follow:

October 9, 2020	$ 5,000 (paid)
October 9, 2021	$ 10,000
Every year thereafter until first sale	$ 25,000

10. FINANCIAL INSTRUMENTS

(a) Fair value

Financial instruments recognized at fair value on the condensed consolidated interim statements of financial position must be classified in one of the following three fair value hierarchy levels:

Level 1 – measurement based on quoted prices (unadjusted) observed in active markets for identical assets or liabilities;

Level 2 – measurement based on in, puts other than quoted prices included in Level 1 that are observable for the asset or liability; or

Level 3 – measurement based on inputs that are not observable (supported by little or no market activity) for the asset or liability.

As at May 31, 2021 and 2020, the Company's financial instruments are comprised of cash and cash equivalents (bank indebtedness), accounts receivables, and accounts payable and accrued liabilities. The carrying amounts reported in the condensed consolidated interim statements of financial position for cash and cash equivalents (bank indebtedness), receivables, and accounts payable and accrued liabilities approximate fair values due to the short-term maturities of these financial instruments.

(b) Credit risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents (bank indebtedness). The Company limits its exposure to credit loss by placing its cash and cash equivalents (bank indebtedness) with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure.

(c) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meets its financial obligations as they become due. The Company's approach to managing liquidity is to ensure that it will have sufficient funds to meet its liabilities when due.

At May 31, 2021, the Company had cash and cash equivalents of $155,048 (November 30, 2020: $nil) available to apply against short-term business requirements and current liabilities of $451,605 (November 30, 2020: $473,053). All of the liabilities presented as accounts payable and accrued liabilities are due within 90 days of May 31, 2021.

(d) Currency risk

The Company is exposed to currency risk to the extent expenditures incurred or funds received and balances maintained by the Company are denominated in currencies other than the Canadian dollar. The Company does not manage currency risks through hedging or other currency management tools.

(Expressed in Canadian Dollars)

10. FINANCIAL INSTRUMENTS (continued)

(d) Currency risk (continued)

As at May 31, 2021 and 2020, the Company's net exposure to foreign currency risk is as follows:

US dollars	2021	2020
	$	$
Cash (Bank indebtedness)	68,354	74,348
Accounts receivable	9,500	-
Accounts payable	(175,035)	(304,440)
Short-term loan	(120,000)	-
Net exposure to foreign currency risk	(217,181)	(230,092)
Canadian dollar equivalent	(262,181)	(317,227)

Based on the above net foreign currency exposure, and assuming all other variables remain constant, a 7% weakening or strengthening of the Canadian dollar against the US dollar would have a significant effect on the Company's net loss and comprehensive loss.

(e) Other price risk

Other price risk is the risk that future cash flows of a financial instrument will fluctuate due to changes in market prices, other than those arising from interest rate risk or foreign currency risk. The Company is not exposed to significant other price risk.

11. RESEARCH AND DEVELOPMENT

During the six months ended May 31, 2021, the Company incurred $77,624 (May 31, 2020: $29,767) in research and development expenditures against income of $377,142 (May 31, 2020: $nil) in funding from SōRSE (Note 6).

12. SEGMENTED INFORMATION

The Company has one operating segment, biotechnology research and development with lab and computer equipment in the United States of America.

13. EVENTS SUBSEQUENT TO THE PERIOD

Subsequent to May 31, 2021, the Company was awarded a grant of US$343,750 from the National Cancer Institute of the US National Institutes of Health (NIH). This two-year award will fund development of Pascal's antibody drug for Acute Lymphoblastic Leukemia (ALL), which is the most common childhood leukemia.